ライフサイエンスコーパス: IgG4-RD

1 IgG4-RD can affect any organ and has a heterogeneous pre

2 IgG4-RD is a multiorgan autoimmune disorder characterize

3 IgG4-RD is characterized by a lymphoplasmacytic infiltra

4 IgG4-RD lesions are infiltrated by T helper cells, which

5 IgG4-RD should be added to the causes of cutaneous pseud

6 IgG4-RD should be considered in patients with unusual ne

7 IgG4-RD was confirmed by very high IgG4+ to IgG+ plasma

8 38(hi) plasmablasts are a hallmark of active IgG4-RD.

9 peripheral blood of 84 patients with active IgG4-RD were analyzed by using flow cytometry.

10 G4(+), are increased in patients with active IgG4-RD.

11 in tissue are hallmarks of the disease, and IgG4-RD is associated with increased IgG4 serum levels.

12 xteen patients with histologically confirmed IgG4-RD, 11 patients with sarcoidosis, and 30 healthy su

13 cular immunoglobulin (Ig)G4-related disease (IgG4-RD) and marginal zone lymphomas (MZLs).

14 IgG4-related disease (IgG4-RD) is a fibroinflammatory disorder that can affect

15 IgG4-related disease (IgG4-RD) is a poorly understood, multiorgan, chronic inf

16 IgG4-related disease (IgG4-RD) is a systemic fibroinflammatory condition affec

17 Immunoglobulin G4 (IgG4)-related disease (IgG4-RD) is an immune-mediated condition that can affect

18 IgG4-related disease (IgG4-RD) is characterized by a lymphoplasmacytic infiltr

19 IgG4-related disease (IgG4-RD) is characterized by an inflammatory reaction ri

20 Immunoglobulin G4 (IgG4)-related disease (IgG4-RD) of the biliary tree and pancreas is difficult t

21 In IgG4-related disease (IgG4-RD), skin involvement is rare and associated especi

22 been proposed that allergic mechanisms drive IgG4-RD.

23 The role of B cells and IgG4 antibodies in IgG4-RD pathogenesis is not well defined.

24 h2 and regulatory T-cell (Treg) cytokines in IgG4-RD and in IgG4-associated MZL and IgG4-negative MZL

25 Rituximab-induced B cell depletion in IgG4-RD leads to rapid clinical and histological improve

26 ocrine gland antigens have been described in IgG4-RD, whether they are members of the IgG4 subclass i

27 autoreactive IgG4 antibodies are observed in IgG4-RD, there is no evidence that they are directly pat

28 uld be considered as a therapeutic option in IgG4-RD.

29 Head and brain involvement is rare in IgG4-RD, and brain parenchyma involvement has never been

30 hat Th2 responses that have been reported in IgG4-RD may result from concomitant atopic manifestation

31 bution of atopy to enhanced Th2 responses in IgG4-RD.

32 A man in his mid-50s with multiorgan IgG4-RD developed progressive spastic hemiparesis and de

33 Ocular IgG4-RD and IgG4-associated MZL exhibited significantly

34 The recognition and diagnosis of IgG4-RD are crucial because the disease responds favorab

35 The diagnosis of IgG4-RD unifies many eponymous fibroinflammatory conditi

36 sensitive nor specific for the diagnosis of IgG4-RD.

37 ineation, early diagnosis, and monitoring of IgG4-RD of the biliary tree and pancreas.

38 bset of ocular MZLs arises in the setting of IgG4-RD.

39 We report 2 cases of isolated skin IgG4-RD successfully treated with thalidomide and invest

40 discusses the IgG4-related disease spectrum (IgG4-RD), the autoimmune polyglandular syndromes (APS),

41 It has been suggested that IgG4-RD is characterized by allergic manifestations and

42 The contribution of autoantibodies to IgG4-RD remains unclear.

43 d IgE, suggesting that processes inherent to IgG4-RD itself rather than atopy per se contribute to th

44 monstrate that the majority of patients with IgG4-RD are nonatopic.

45 ease, and a high proportion of patients with IgG4-RD are reported to have longstanding allergies, per

46 We evaluated patients with IgG4-RD for activated B cells in both disease lesions an

47 arameters in a large cohort of patients with IgG4-RD in whom a wide range of organs were affected by

48 Furthermore, patients with IgG4-RD, but not patients with sarcoidosis, had increase

49 phocyte signature" observed in patients with IgG4-RD, could support diagnosis and treatment monitorin

50 dysregulated IgG4 response in patients with IgG4-RD.

51 ns has ever been undertaken in patients with IgG4-RD.

52 common disease pathogenesis in patients with IgG4-RD.

53 lood IgG4(+) memory B cells in patients with IgG4-RD.